Patents Expiring in December 2039
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | ⤷ Get Started Free | ⤷ Get Started Free | TREATMENT OF PHARMACOLOGICALLY-INDUCED MYDRIASIS | ||||
| Deciphera Pharms | ROMVIMZA | vimseltinib | CAPSULE;ORAL | 219304-001 | Feb 14, 2025 | RX | Yes | No | ⤷ Get Started Free | ⤷ Get Started Free | TREATMENT OF TENOSYNOVIAL GIANT CELL TUMOR | ||||
| Deciphera Pharms | ROMVIMZA | vimseltinib | CAPSULE;ORAL | 219304-002 | Feb 14, 2025 | RX | Yes | No | ⤷ Get Started Free | ⤷ Get Started Free | TREATMENT OF TENOSYNOVIAL GIANT CELL TUMOR | ||||
| Deciphera Pharms | ROMVIMZA | vimseltinib | CAPSULE;ORAL | 219304-003 | Feb 14, 2025 | RX | Yes | Yes | ⤷ Get Started Free | ⤷ Get Started Free | TREATMENT OF TENOSYNOVIAL GIANT CELL TUMOR | ||||
| Iterum Therap | ORLYNVAH | probenecid; sulopenem etzadroxil | TABLET;ORAL | 213972-001 | Oct 25, 2024 | RX | Yes | Yes | ⤷ Get Started Free | ⤷ Get Started Free | Y | USE IN TREATING UNCOMPLICATED URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR PROTEUS MIRABILIS | |||
| Rvl Pharms | UPNEEQ | oxymetazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 212520-001 | Jul 8, 2020 | RX | Yes | Yes | ⤷ Get Started Free | ⤷ Get Started Free | METHOD OF TREATING BLEPHAROPTOSIS | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
